Authors' objectives: What are the evidence-based guidelines regarding the use of growth hormone therapy for children with Short Stature Secondary to Small for Gestational Age?What are the evidence-based guidelines regarding the use of growth hormone therapy for children with Idiopathic Short Stature?

Authors' results and conclusions: · For children with short stature who were born small for gestational age, 1 guideline suggests increasing human growth hormone dose when treatment response is unsatisfactory, while aiming for normal insulin-like growth factor 1 levels. · For children with idiopathic short stature, 1 guideline recommends against the routine use of growth hormone. It suggests initiating growth hormone therapy on a case-by-case basis, with a starting dose ranging from 0.24 mg/kg/week to 0.47 mg/kg/week, as well as conducting an assessment 12 months after initiation to optimize dosage. · The development of recommendations from guidelines included in this report was challenged by limited relevant evidence, as well as heterogeneity of growth hormone dose and frequency and treatment response found in available literature. Future guidelines should also consider patient perspectives, resource implications, and the facilitators of and barriers to therapy within the context of health care systems in Canada.

Project Status: Completed

URL for project: https://www.cadth.ca/somatropin-short-stature

Year Published: 2023

URL for published report: https://www.cadth.ca/somatropin-short-stature

English language abstract: An English language summary is available

Publication Type: Rapid Review

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>